Introduction to the updated Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting, 2008.
The process for development of these consensus Australasian antifungal guidelines for use in adult patients with haematological malignancy is described. New features included, how the guidelines should be applied, the risk assessment tool used and the grading system for evidence and strength of recommendation are discussed.
Slavin
M A
MA
Clinical Centre of Research Excellence in Infectious Diseases, Royal Melbourne Hospital, Melbourne, VIC. Monica.Slavin@petermac.org
D000935:Antifungal Agents / Q000627:therapeutic use*; D006801:Humans; D009181:Mycoses / Q000150:complications* / Q000188:drug therapy*; D009369:Neoplasms / Q000150:complications*; D009503:Neutropenia / Q000150:complications*; D009894:Opportunistic Infections / Q000150:complications* / Q000188:drug therapy*; D017410:Practice Guidelines as Topic
D000935:Antifungal Agents